151 related articles for article (PubMed ID: 36377026)
1. Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.
Karacin C; Bilgetekin I; Basal FB; Oksuzoglu OB
J Coll Physicians Surg Pak; 2022 Nov; 32(11):1501-1502. PubMed ID: 36377026
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
[TBL] [Abstract][Full Text] [Related]
3. Ado-trastuzumab emtansine associated spider telangiectasia.
Gursoy P; Acar A; Acikalin T
J Oncol Pharm Pract; 2022 Jun; 28(4):986-988. PubMed ID: 35040682
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
5. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
Bellon JR; Tayob N; Yang DD; Tralins J; Dang CT; Isakoff SJ; DeMeo M; Burstein HJ; Partridge AH; Winer EP; Krop IE; Tolaney SM
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):117-124. PubMed ID: 34990776
[TBL] [Abstract][Full Text] [Related]
6. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
7. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
Lepelley M; Allouchery M; Long J; Boucherle D; Ranchoup Y; Le Marc'Hadour F; Villier C; Sturm N
Ann Hepatol; 2018 Oct; 17(6):1067-1071. PubMed ID: 30600283
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
Salvestrini V; Kim K; Caini S; Alkner S; Ekholm M; Skyttä T; Becherini C; Coles CE; Kaidar-Person O; Offersen B; de Azambuja E; Visani L; Cortes J; Harbeck N; Rugo HS; Isacke CM; Marangoni E; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
Radiother Oncol; 2023 Sep; 186():109805. PubMed ID: 37437610
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
Huang CS; Yang Y; Kwong A; Chen SC; Tseng LM; Liu MC; Shen K; Wang S; Ng TY; Feng Y; Sun G; Yan IR; Shao Z
Breast Cancer Res Treat; 2021 Jun; 187(3):759-768. PubMed ID: 33860389
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-emtansine induced pleural and pericardial effusions.
Lombardi J; Lory P; Martin N; Mayeur D; Combret S; Grandvuillemin A; Boulay C; Schmitt A
J Oncol Pharm Pract; 2021 Dec; 27(8):2041-2044. PubMed ID: 34000917
[TBL] [Abstract][Full Text] [Related]
12. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
Muzaffar M; Jia J; Liles D; Naveed M; Kumari A
Am J Ther; 2016; 23(2):e572-4. PubMed ID: 25756468
[TBL] [Abstract][Full Text] [Related]
13. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
[TBL] [Abstract][Full Text] [Related]
14. [Clinical research progress of T-DM1 in breast cancer].
Li LX; Ma F
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):92-97. PubMed ID: 33472319
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
Montemurro F; Delaloge S; Barrios CH; Wuerstlein R; Anton A; Brain E; Hatschek T; Kelly CM; Peña-Murillo C; Yilmaz M; Donica M; Ellis P
Ann Oncol; 2020 Oct; 31(10):1350-1358. PubMed ID: 32634611
[TBL] [Abstract][Full Text] [Related]
16. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract][Full Text] [Related]
17. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
18. Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab.
LaMorte D; Desmond D; Ellis J; Lipkowitz S
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479891
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence.
Giuliani J; Bonetti A
Breast J; 2021 Jan; 27(1):75-76. PubMed ID: 32920921
[No Abstract] [Full Text] [Related]
20. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]